Interferon-γ+ and interleukin-2+ T cells in peripheral blood from multiple myeloma patients in relation to disease status and maintenance therapy with interferon-α2b (intron A)

British Journal of Haematology

Volumn 98, Issue 1, 1997, Pages 119-125

  Millar, Barbara C ^a   Millar, J L ^a   Powles, R L ^a   Catovsky, D ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Interferon ; Interferon ; Interleukin 2; Myeloma; T cells

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 6; RECOMBINANT ALPHA2B INTERFERON;

ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DISEASE ACTIVITY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 0030852052     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1997.1782995.x     Document Type: Article

References (48)

1. Attal, M., Harousseau, J.L., Stoppa, A., Sotto, J.J., Fuziget, J.G., Rossi, J.F., Cacassus, P., Maisseuve, H., Facon, T., Ifrah, N., Payen, C. & Bataille, R. (1996) A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New England Journal of Medicine, 335, 91-97.
2. Attal, M., Huguet, F., Schlaifer, D., Payen, C., Laroche, M., Fournie, B., Mazieres, B., Pris, J. & Laurent, G. (1992) Intensive therapy for previously untreated myeloma. Blood, 79, 1130-1136.
3. Bell, J.G.B., Barfoot, R., Iveson, T., Powles, R.L. & Millar, B.C. (1944) Neuralising antibodies in patients with multiple myeloma receiving maintenance therapy with Interferon α2b. British Journal of Cancer, 70, 646-651.
4. Bergenbrant, S., Yi, Q., Osterborg, A., Bjorkholm, M. Osby, E., Mellstadt, H., Lefvert, A.K. & Holm, G. (1496) Modulation of antiidiotypic response by immunization with autologous protein in multiple myeloma patients. British Journal of Haematology, 92, 840-846.
5. Bergmann, P., Mitou, P.S., Weber, K.C. & Kelker, W. (1984) Imbalance of T-cell subsets in monclonal gammopathies. Cancer Immunology and Immunotherapy, 17, 112-116.
6. 2 inhibits the production of Th1 lymphokines but not Th2 lymphokines. Journal of Immnology, 146, 108-113.
7. + cells. British Journal of Haematology, 90, 625-632.
8. Boyum, A. (1968) Separation of leucocytes from blood and bone marrow. Scandinavian Journal of Clinical and Laboratory Investigation, 21, 1-6.
9. Bretcher, P. (1992) The two-signal model of lymphocyte activation twenty-one years later. Immunology Today, 13, 74-76.
10. Chasty, R.C., Lamb, W.R., Gallati, H., Roberts, T.E., Brenchley, P.E.C. & Yin, L. (1993) Serum cytokine levels in patients undergoing bone marrow transplantation. Bone Marrow Transplantation, 12, 331-336.
11. Cimino, G., Avvisata, G., Amadori, S., Cava, M.C., Giannarelli, D., DiNucci, G.D., Magliocca, V., Petrucci, M.T., Poti, G. & Sgadari, C. (1990) High serum levels of IL-2 are predictive of prolonged survival in multiple myeloma patients. British Journal of Haematology, 75, 373-377.
12. Cunningham, D., Powles, R.L., Malpas, J.S., Milan, S., Meldrum, M., Viner, C., Montes, A., Hickish, T., Nicholson, M., Johson, P., Mansi, J., Treleaven, J., Raymond, J. & Gorem, M.E. (1993) A randomised trial of maintenance therapy with intron-A following high-dose melphalan and ABMT in myeloma. British Journal of Cancer, 67, (Suppl. XX), 30.
13. DeMayer, E. & DeMayer-Guinard, J. (1988) Interferons and Regulatory Cytokines. John Wiley & Sons, New York.
14. Demeure, C.E., Wu, C.Y., Shu, U., Schneider, P.V., Heusser, C., Ysel, H. & Delespesse, G. (1994) In vitro maturation of human neonatal CD4 T lymphocytes. II. Cytokines present at priming modulate the development of lymphokine production. Journal of Immunology, 152, 4775-4782.
15. Dianzini, U., Pileri, A., Boccadoro, M., Palumbo, A., Pioppo, P., Bianchi, A., Camponi, A., Battaglio, S. & Massaia, M. (1988) Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis of disease status. Blood, 72, 1064-1068.
16. Einhorn, S., Ahre, A., Blomgren, H., Johansson, B. & Mellstedt, H. (1982) Interferon and natural killer activity in multiple myeloma: lack of correlation between interferon-induced enhancement of natural killer activity and clinical response to human interferon-α. International Journal of Cancer, 30, 167-172.
17. Erard, F., Corthesy, P., Nabholtz, M., Lowenthal, J.W., Zaech, P., Plaetinck, G. & MacDonald, H.R. (1985) Interleukin 2 is both necessary and sufficient for the growth and differentiation of lectin-stimuiated T lymphocytes precursors. Journal of Immunology, 134, 1644-1652.
18. Gottlieb, D.J., Prentice, G.H., Mehta, A.B., Galazka, A.R., Heslop U.E., Hoffbrand, A.V. & Brenner, M.K. (1990) Malignant plasma cells are sensitive to pre-clinical and clinical studies of interleukin 2 in the treatment of multiple myeloma. British Journal of Haematology, 75, 499-505.
19. 1. Journal of Immmunology, 131, 768-772.
20. Hauch, M., Gizzola, M.V., Small, T., Bordgnon, C., Barnet, L., Cunningham, I., Castro-Malaspania, H., O'Reilly, R.J. & Keever, C.A. (1990) Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood, 75, 2250-2262.
21. Hoover, R.G. & Kornbluth, J. (1992) Immunoregulation of murine and human myeloma. Hematology/Oncolgy Clinics of North America, 6, 407-424.
22. Hjorth, M., Westin, J., Dahl, I.M.S., Gimsing, P., Hippe, E., Holmberg, E., Lamvik, J., Nielsen, J.L., Lofvenberg, E., Palva, I.P., Rodgers, S., Talstad, I., Turesson, I., Wisloff, F. & Zador, G. (1996) Interferonalpha 2b added to melphalan-prednisolone for initial maintenance therapy in multiple myeloma: a randomised, controlled trial. Annals of Internal Medicine, 124, 212-222.
23. Jagganath, S., Crowley, J., Vesole, D., Naucke, S., Bracy, D., Barlogie, B. & Tricot, G. (1995) Interferon-alpha (IFN) may improve event-free (EFS) and overall survival (OS) in multiple myeloma (MM) following double blind autotransplants (DAT). Proceedings of the Annual Meeting of the American Sociaty for Clinical Oncology, 14, 1354.
24. Joshua, D.E. (1988) Biology of multiple myeloma-host-tumour interactions und immune regulation of disease activity. Haematological Oncology, 6, 83-88.
25. Kanawa, M., Hirano, T., Matsuda, T., Taga, T., Horr, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O. & Kishimoto, T. (1988) Autocrine generation and requirement of BSF-2/II.-6 for human multiple myeloma. Nature, 332, 83-85.
26. Klein, B. & Bataille, R. (1992) Cytokine network in human multiple myeloma. Hematology/Oncology Clinics of North America, 6, 273-284.
27. Klein, B., Xue-Guang, Z., Jourdan, M., Content, J., Houssiau, F., Aarden, L., Piechaczyk, M. & Bataille, R. (1989) Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Biood. 75, 517-526.
28. Ludwig, H., Cohen, A.M., Poliack, A., Huber, H., Nachbaur, D., Senn, H.J., Morant, R., Eckhardt, S., Gunczler, P., Seewan, H.L., Schuller, J., Rhyner, K., Cavalli, F. & Fritz, E. (1995) Interferonalpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies. Annals of Oncology, 6, 457-476.
29. Massaia, M., Bianchi, A., Attisano, C., Peola, C., Redoglia, V., Dianzini, U. & Pileri, A. (1991) Detection of hyperreactive T-cells in multiple myeloma by multivalent cross-linking of the CD3/TCR complex. Blood, 78, 1770-1780.
30. Medenica, R., Powell, D., Long, P. & Corbitt, W. (1996) Identification and monitoring of naturally occurring interferon inhibitor factor using How cytometry. Experimental Haematology, 24, 1087.
31. Millar, B.C., Bell, J.B.G., Lakhanii, A., Ayliffe, M.J., Selby, P.J. & McElwain, T.J. (1988) A simple method for culturing myeloma cells from human bone marrow aspirates and peripheral blood in vitro. British Journal ofHaematology, 69, 197-203.
32. Millar, B.C., Bell, J.B.G. & Powles, R.L. (1996) Lymphocyte recovery and clinical response in multiple myeloma patients receiving interferon-α2b after intensive therapy. British Journal of Cancer, 73, 236-240.
33. Mossman, T.R. & Coffman, R.L. (1989) TH1 and TH2 cells: different patterns of lymphokine secretion lead to different properties. Annual Review of Immunology, 7, 145-173.
34. Neiderweisser, D., Herold, D., Wloszcuk, W., Autitzky, W., Meister, B., Tig, H., Gastl, G., Bowden, R. & Huber, C. (1990) Endogenous interferon and human bone marrow transplantation: analysis of serum levels of interferon and interferon-dependent secondary message. Transplantation, 50, 620-625.
35. Osterborg, A., Bjorkholm, B., Holm, G. & Mellstadt, H. (1990) Natural killer cell activity in monoclonal gammopathies: relation to disease activity. European Journal of Haematology, 45, 153-157.
36. - T-cell clones. Journal of Immunology, 141, 849-855.
37. Palumho, A., Bruno, B., Boccadoro, M. & Pileri, A. (1995) Interferon-gamma in multiple myeloma. Leukaemia and Lymphoma, 18, 215-219.
38. H2 human T-cell colonies. Journal of Immunology, 149, 2977-2983.
39. Portier, M., Zhang, X-G., Caron, E., Lu, Z-Y., Bataille, R. & Klein, B. (1995) Gamma interferon in multiple myeloma: inhibition of interleukin-6 (IL-6)-dependent myeloma cell growth and down-regulation of IL-6-receptor expression in vitro. Blood, 81, 3076-3082.
40. Powles, R., Raje, N., Cunningham, D., Malpas, J., Milan S., Horton, C., Mehta, J., Singhal, S., Viner, C. & Treleaven, J. (1995) Maintenance therapy for remission in myeloma with intron A following high dose melphalan and either autologous bone marrow or peripheral stem cell rescue. Stem Cells, 13, (Suppl. 2), 114-117.
41. Raff, M.C. (1992) Social controls on cells survival and cell death. Nature, 356, 397-400.
42. Reittie, J.E., Gottleib, G., Heslop, H.E., Leger, O., Hazlehurst, G., Hoftbrand, V.A., Prentice, H.G. & Brenner, M.K. (1989) Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation hut not after chemotherapy, Blood, 73, 1351-1358.
43. H2 response: a key role for the 'natural' immune response. Immunology Today, 13, 379-385.
44. Salmon, S.E., Crowley, J.J., Grogan, T.M., Finley, P., Pugh, R.P. & Barlogie, B. (1994) Combination chemotherapy, glucocorticoids, and Interferon alpha in the treatment of multiple myeloma: a Southwest Oncology Group Study. Journal of Clinical Oncology, 12, 2405-2414.
45. Schmidt, J., Fleissner, S., Heimann-Weitschat, I., Lindstuedt, R., Werner, U. & Szelenyi, I. (1994) Effect of corticosteroids. cyclosporin A, and methotrexate on cytokine release from monocytes and T-cell subsets, Immunopharmacology, 27, 173-179.
46. Simon, M.M., Landolfo, S., Diamanstein, T. & Hochgeschwender, U. (1986) Antigen- and lectin-sensitized murine cytolytic T lymphocyte precursors require both interleukin 2 and endogenously produced immune (gamma) Interferon for their growth and differentiation into effector cells. Current Topics in Microbiology and Immunology, 126, 173-185.
47. Uchida, A., Masata, Y., Sugiyama, H., Hoshino, T. & Moore, M. (1984) Strong natural killer (NK) cell activity in hone marrow on myeloma patients: accelerated maturation of bone marrow NK cells and their interaction with other bone marrow cells. International Journal of Cancer, 34, 375-381.
48. Ulrich, S. & Zolla-Pazner, S. (1982) Immunoregulatory circuits in myeloma. Clinical Haematology, 11, 87-111.